--- title: "According to \"The Big Banks,\" Bank of America Securities has lowered the target price for WUXI BIO to 39.5 yuan with a rating of \"Neutral.\"" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/280565252.md" description: "Bank of America Securities released a report stating that WUXI BIO's revenue last year increased by 16.7% year-on-year to 21.8 billion RMB, with a gross profit of 10 billion RMB and a gross margin rising to 46%. The net profit was 4.9 billion RMB, a year-on-year increase of 46.3%. The bank has lowered its revenue forecasts for 2026 to 2028 by 4% to 8%, reduced the gross margin by 0.4 percentage points, and decreased the target price from 47 RMB to 39.5 RMB, maintaining a \"Neutral\" rating" datetime: "2026-03-26T04:02:04.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/280565252.md) - [en](https://longbridge.com/en/news/280565252.md) - [zh-HK](https://longbridge.com/zh-HK/news/280565252.md) --- > 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280565252.md) | [English](https://longbridge.com/en/news/280565252.md) # According to "The Big Banks," Bank of America Securities has lowered the target price for WUXI BIO to 39.5 yuan with a rating of "Neutral." Bank of America Securities published a research report stating that WUXI BIO (02269.HK) had a revenue increase of 16.7% year-on-year to RMB 21.8 billion last year, in line with expectations. The gross profit reached RMB 10 billion, with a gross margin increase of 5 percentage points to 46%, benefiting from a higher contribution from royalties or milestone revenues and improved capacity utilization. The net profit attributable to shareholders was RMB 4.9 billion, an increase of 46.3% compared to the same period last year. The bank indicated that it has lowered its revenue forecasts for 2026 to 2028 by 4% to 8%, and reduced the gross margin by 0.4 percentage points. The target price has been lowered from RMB 47 to RMB 39.5, with a rating of "Neutral." ### 相關股票 - [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md) - [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md) - [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md) - [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md) - [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md) - [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md) - [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md) - [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md) - [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md) - [WUXI BIO (02269.HK)](https://longbridge.com/zh-HK/quote/02269.HK.md) - [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md) - [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md) - [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md) - [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md) - [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md) - [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md) - [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md) - [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md) - [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md) - [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md) - [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md) ## 相關資訊與研究 - [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/zh-HK/news/280992698.md) - [Clover Biopharmaceuticals Completes Enrollment in Phase 2 Trial for Combination Respiratory Vaccines](https://longbridge.com/zh-HK/news/280923090.md) - [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md) - [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md) - [RemeGen Receives Chinese Regulatory Nod for RC288 Clinical Trial](https://longbridge.com/zh-HK/news/281458440.md)